Material ESG topics for pharmaceuticals
A sector-informed shortlist of the topics most likely to be material, each mapped to the BRSR principle it lives under. A starting point for the client's own stakeholder-driven materiality assessment, not a finished one.
Active pharmaceutical ingredient (API) effluent and antibiotic contamination
API manufacturing discharges (especially from Hyderabad, Baddi, Vapi clusters) contribute to antimicrobial resistance in waterways; regulatory scrutiny on ZLD and effluent quality is intensifying.
Solvent use, VOC emissions, and hazardous waste from synthesis
Chemical synthesis generates significant hazardous waste and volatile organic compound emissions; state PCB compliance, TSDF utilisation, and waste minimisation are core environmental metrics.
GHG emissions from energy-intensive API manufacturing
Batch chemical processing, clean rooms, and HVAC systems drive high energy consumption; BRSR Core requires Scope 1 and 2 intensity disclosure with third-party assurance.
Water consumption in formulation and API processes
Pharmaceutical manufacturing requires high-purity water (WFI, purified water) with significant intake-to-output ratios; water-stressed locations face regulatory restrictions.
Packaging waste and EPR for pharma packaging
Blister packs, glass vials, and multi-layer packaging generate post-consumer waste; EPR obligations under Plastic Waste Management Rules require collection and recycling commitments.
India's role as 'pharmacy of the world' makes drug affordability a core social responsibility; DPCO price controls, voluntary licensing, and tiered pricing are material topics.
CDSCO regulations require informed consent, compensation for adverse events, and ethics committee oversight; clinical trial governance is a high-stakes human rights and product responsibility issue.
Worker health and safety in chemical processing environments
Workers face chemical exposure, solvent vapour inhalation, and dust hazards in API manufacturing; occupational health monitoring and PPE compliance are critical BRSR metrics.
Import bans and FDA warning letters carry massive financial and reputational impact; quality governance systems are material for market access and investor confidence.
Anti-bribery and anti-corruption in procurement and distribution
Pharmaceutical industry faces endemic corruption risk in tendering, hospital procurement, and distributor relationships; BRSR Principle 1 requires anti-corruption policy and incident disclosure.
ESG data systems and BRSR Core assurance readiness
Listed pharma companies face expanding BRSR assurance obligations; many still track environmental data on spreadsheets that fail audit scrutiny.
Example listed pharmaceuticals companies
Indian listed pharmaceuticals companies that file BRSR. Useful reference points when benchmarking a client's disclosures.
Frequently asked questions
Which BRSR principles matter most for pharmaceuticals companies?
Across the material topics for the pharmaceuticals sector, the disclosures cluster around P6, P9, P8, P1, P5. Principle 6 (Environment) is almost always the heaviest, but the exact priority depends on the company's operations and value chain.
Does my pharmaceuticals company have to file BRSR?
The top 1000 listed companies by market capitalisation must file BRSR. If your company is listed on an Indian exchange and in that bracket, yes. Unlisted companies may still be pulled in as significant value-chain partners of a larger listed company.
What are the most material ESG topics for the pharmaceuticals sector?
The topics that typically matter most include Active pharmaceutical ingredient (API) effluent and antibiotic contamination, Solvent use, VOC emissions, and hazardous waste from synthesis, GHG emissions from energy-intensive API manufacturing, Water consumption in formulation and API processes. A credible materiality assessment still needs the company's own stakeholder engagement, but this is the sector-informed starting point.
How do I know which BRSR data a pharmaceuticals company already has?
Much of it sits in filings the company already submits, such as Pollution Control Board consents, PAT returns and hazardous-waste manifests. Saaksh's free gap analysis maps those filings against all 108 BRSR fields and shows exactly what is already covered versus what to collect.
Gap-analyse a pharmaceuticals client's BRSR
A two-minute intake becomes a cited, gap-analysed action plan across all 108 BRSR fields, with built-in emissions calculators. Free, on your device.